Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.41 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.40 |
| ▸ | MAPT | P10636 | 6/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | RAF1 | P04049 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6543570 | 0.93 | MERTK (0.40) | MEN1KMT2APOLBMCOLN3SMN1; SMN2 | |
| SCHEMBL7815112 | 0.90 | POLB (0.50) | MEN1KMT2APOLBMCOLN3AKR1C3 | |
| SCHEMBL6176387 | 0.88 | MEN1 (0.44) | MEN1KMT2APOLBMCOLN3AKR1C3 | |
| SCHEMBL27939697 | 0.88 | MEN1 (0.40) | MEN1KMT2APOLBMCOLN3RAB9A | |
| SCHEMBL27921215 | 0.87 | MEN1 (0.36) | MEN1KMT2APOLBMCOLN3AKR1C3 | |
| SCHEMBL3487495 | 0.85 | ALDH1A1 (0.41) | MEN1KMT2APOLBMCOLN3SMN1; SMN2 | |
| SCHEMBL6544430 | 0.85 | MMP13 (0.42) | AKR1C3AKR1C2SMN1; SMN2AKR1B10AKR1B1 | |
| SCHEMBL27939756 | 0.84 | KMT2A (0.39) | MEN1KMT2APOLBSMN1; SMN2RAB9A | |
| SCHEMBL27939703 | 0.84 | CYP19A1 (0.38) | MEN1KMT2APOLBSMN1; SMN2RAB9A | |
| SCHEMBL10136028 | 0.84 | TSHR (0.45) | KMT2APOLBMCOLN3ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0753298-B2 | Synergistic combination comprising an insulin sensitizer and a HMG-CoA reductase inhibitor for treating arteriosclerosis | SANKYO CO (JP) | 2011-02-16 | — | — | EP | disclosed |
| EP-1607385-A1 | Intermediates for the synthesis of benzimidazole compounds and process for the preparation thereof | Sankyo Company Limited (JP) | 2005-12-21 | — | — | EP | disclosed |
| EP-1172356-B1 | Process for producing N-acylnitroaniline derivative | SUMITOMO CHEMICAL CO (JP) | 2004-10-06 | — | — | EP | disclosed |
| US-6753347-B2 | CONDENSATION OF AMINE DERIVATIVE WITH CARBOXYLIC ACID DERIVATIVES TO AFFORD INTERMEDIATE COMPOUND, FOLLOWED BY CYCLIZATION OF INTERMEDIATE COMPOUND IN PRESENCE OF ACID; HYOPOGLYCEMIC ACTION | SANKYO COMPANY, LIMITED (JP) | 2004-06-22 | — | — | US | disclosed |
| US-20030199580-A1 | Intermediates for the synthesis of benzimidazole derivatives and a process for the preparation thereof | SANKYO COMPANY, LIMITED (JP) | 2003-10-23 | — | — | US | disclosed |
| US-6630598-B2 | Reacting nitroaniline compound with acid chloride/anhydride in presence of alkali metal/earth metal compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-10-07 | — | — | US | disclosed |
| US-6525220-B2 | Having hypoglycemic action | SANKYO COMPANY, LIMITED (JP) | 2003-02-25 | — | — | US | disclosed |
| US-20030008907-A1 | Intermediates for the synthesis of benzimidazole derivatives and a process for the preparation thereof | SANKYO COMPANY, LIMITED (JP) | 2003-01-09 | — | — | US | disclosed |
| EP-1191019-A1 | INTERMEDIATES FOR THE SYNTHESIS OF BENZIMIDAZOLE COMPOUNDS AND PROCESS FOR THE PREPARATION THEREOF | Sankyo Company, Limited (JP) | 2002-03-27 | — | — | EP | disclosed |
| US-20020016506-A1 | Process for producing N-acylnitroaniline derivative | SUMITOMO CHEMICAL COMPANY, LIMITED | 2002-02-07 | — | — | US | disclosed |
| EP-1172356-A1 | Process for producing N-acylnitroaniline derivative | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-01-16 | — | — | EP | disclosed |
| EP-0753298-B1 | Synergistic combination comprising an insulin sensitizer and a HMG-CoA reductase inhibitor for treating arteriosclerosis | SANKYO CO (JP) | 2001-11-21 | — | — | EP | disclosed |
| EP-0745600-B1 | Benzimidazole derivatives, their preparation and their therapeutic use | SANKYO CO (JP) | 2001-10-24 | — | — | EP | disclosed |
| US-6159997-A | Treatment of arteriosclerosis and xanthoma | SANKYO COMPANY, LIMITED (JP) | 2000-12-12 | — | — | US | disclosed |
| US-5886014-A | TREATMENT AND/OR PROPHYLAXIS OF A VARIETY OF DISORDERS, INCLUDING HYPERLIPEMIA, HYPERGLYCEMIA, OBESITY, IMPAIRED GLUCOSE TOLERANCE (IGT), INSULIN RESISTANCE AND DIABETIC COMPLICATIONS | SANKYO COMPANY, LIMITED (JP) | 1999-03-23 | — | — | US | disclosed |
| US-5798375-A | ADMINISTERING TO THE PATIENT PREVASTATIN A HYDROXY-3-METHYL-GLUTARYL/3-/ COENZYME A REDUCTASE INHIBITOR AND A INSULIN SENSITIZER TROGLITAZONE | SANKYO COMPANY, LIMITED (JP) | 1998-08-25 | — | — | US | disclosed |
| EP-0753298-A1 | Synergistic combination comprising an insulin sensitizer and a HMG-CoA reductase inhibitor for treating arteriosclerosis | SANKYO COMPANY LIMITED (JP) | 1997-01-15 | — | — | EP | disclosed |
| EP-0745600-A1 | Benzimidazole derivatives, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1996-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008907-A1 | Intermediates for the synthesis of benzimidazole derivatives and a process for the preparation thereof | H1-4, H1-3, GCK | MEN1 170/4885KMT2A 2238/4885POLB 3785/4885 |
| US-20020016506-A1 | Process for producing N-acylnitroaniline derivative | NAAA, NAT1, ACOT7 | MEN1 1076/4885KMT2A 513/4885POLB 3496/4885 |
| US-20030199580-A1 | Intermediates for the synthesis of benzimidazole derivatives and a process for the preparation thereof | H1-4, H1-3, GCK | MEN1 170/4885KMT2A 2238/4885POLB 3785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.